| AJNMMI Copyright © 2011-present, All rights reserved. Published by e-Century Publishing Corporation, Madison, WI 53711, USA |
Am J Nucl Med Mol Imaging 2011;1(1):63-64.
Invited Perspective
18F-FDG PET/CT: timing for evaluation of response to therapy remains a clinical
challenge
Andrei Iagaru
Department of Radiology, Division of Nuclear Medicine, Stanford University Medical Center, Stanford, CA, USA.
Received July 25, 2011; accepted July 29, 2011; Epub July 30, 2011; Published August 15, 2011
Abstract: Utilizing novel imaging modalities for defining response and predicting long-term outcome after treatment may have a
significant impact on cancer patient management. 18F-FDG PET/CT has great potential for use in early assessment of response to
cancer therapy. However, the lack of a general consensus on a specific set of response criteria makes adoption of PET difficult for
the oncology community. The optimal time after initiating therapy for as-sessing response to treatment also has yet to be clearly
determined. (ajnmmi1107001).
Keywords: 18F-FDG, PET/CT, Therapeutic response, Cancer
Full text PDF
Address all correspondence to:
Andrei Iagaru, MD
Department of Radiology
Division of Nuclear Medicine
Stanford University Medical Center
Stan-ford, CA, USA.
E-mail: aiagaru@stanford.edu.
Invited Perspective
18F-FDG PET/CT: timing for evaluation of response to therapy remains a clinical
challenge
Andrei Iagaru
Department of Radiology, Division of Nuclear Medicine, Stanford University Medical Center, Stanford, CA, USA.
Received July 25, 2011; accepted July 29, 2011; Epub July 30, 2011; Published August 15, 2011
Abstract: Utilizing novel imaging modalities for defining response and predicting long-term outcome after treatment may have a
significant impact on cancer patient management. 18F-FDG PET/CT has great potential for use in early assessment of response to
cancer therapy. However, the lack of a general consensus on a specific set of response criteria makes adoption of PET difficult for
the oncology community. The optimal time after initiating therapy for as-sessing response to treatment also has yet to be clearly
determined. (ajnmmi1107001).
Keywords: 18F-FDG, PET/CT, Therapeutic response, Cancer
Full text PDF
Address all correspondence to:
Andrei Iagaru, MD
Department of Radiology
Division of Nuclear Medicine
Stanford University Medical Center
Stan-ford, CA, USA.
E-mail: aiagaru@stanford.edu.
 |  |  |  |  |  |  |